Full Text
COST EFFECTIVENESS OF EMPAGLIFLOZIN/LINAGLIPTIN AS 2ND-LINE THERAPY FOR ADULTS WITH TYPE 2 DIABETES

Abstract

Authors

L.E. Henkhaus J.W. Hay

Back to Volume 19, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×